FDA Approves Mobile App for Abbott’s Freestyle Libre

Published on
By : Suvarna Sheth

A new mobile app for Abbott’s Freestyle Libre 10-day and 14-day glucose monitoring systems has been approved for use in the U.S. by the FDA.

It will allow patients with diabetes to monitor glucose readings on their compatible iPhone by simply holding their iPhone near their FreeStyle Libre or FreeStyle Libre 14-day sensor.

The app will allow users to instantly capture and view their real-time glucose levels, assess their 8-hour glucose history, and see a directional arrow indicating how their glucose is changing, according to a company press release.

The FreeStyle LibreLink app also includes a series of in-app reports that visualize trends and patterns to help patients understand how well they are controlling their glucose.

“We’re committed to liberating people from the many hassles of diabetes management through our life-changing technology and tools,” Jared Watkin, senior vice president of Diabetes Care at Abbott, said in the release.

“The FreeStyle LibreLink app is a digital health tool that integrates glucose data directly on a compatible smartphone so all of the mobile apps that people use every day are in one convenient place. This is another step forward in making glucose monitoring seamlessly fit into a patient’s daily lifestyle — helping them live a fuller, healthier life.”

FreeStyle LibreLink app will be free to download through the Apple App Store in the coming weeks. Once available, people will be able to pair the FreeStyle Libre or FreeStyle Libre 14 day sensors with the app. The Android version of the app is currently under development.

Sources:

  1. Freestyle LibreLink App FDA Approved. 2018, November 1. Abbott. Retrieved: http://www.abbott.com/corpnewsroom/product-and-innovation/freestyle-librelink.html